Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Non-Current Liabilities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a N/A change, with the full-year FY2025 number at $2.1 billion, changed N/A from a year prior.
  • Total Non-Current Liabilities was $2.1 billion for Q4 2025 at Cytokinetics, up from $2.0 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $2.1 billion in Q4 2025 to a low of $340.3 million in Q1 2021.
  • A 5-year average of $1.1 billion and a median of $1.1 billion in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 589.4% in 2021, then grew 6.59% in 2024.
  • Cytokinetics' Total Non-Current Liabilities stood at $593.0 million in 2021, then surged by 89.15% to $1.1 billion in 2022, then rose by 6.81% to $1.2 billion in 2023, then increased by 21.03% to $1.4 billion in 2024, then soared by 41.81% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Total Non-Current Liabilities are $2.1 billion (Q4 2025), $2.0 billion (Q3 2025), and $1.6 billion (Q2 2025).